A discussion unfolds around the impact of intentionally falsified research on Alzheimer's, which has set the field back significantly. The conversation highlights the disparity between the understanding and treatment of Alzheimer's compared to cardiovascular diseases, emphasizing the uncertainty surrounding amyloid therapies and the reliance on biomarkers that lack proven efficacy. The need for a more precise approach in Alzheimer's research is underscored, reflecting the ongoing challenges faced by the medical community.